A leading independent multi-omics service providers in the Americas.

The Company provides a comprehensive portfolio of next-generation sequencing (NGS), proteomics, metabolomics, epigenomics, and bioinformatics solutions to research institutions, hospitals, biotechnology companies, and pharmaceutical clients across North and South America.

Following the transaction, the Company will become a fully independent platform with significant opportunities for organic expansion, operational optimization, and strategic acquisitions.

Investment Highlights

1. Attractive Exposure to High-Growth Precision Medicine

The global sequencing services market continues to expand at approximately 20% CAGR, driven by precision medicine, drug discovery, oncology, genomics research, and increasing outsourcing by pharmaceutical companies.

The Company is exceptionally well positioned to capitalize on these structural growth trends.

2. Established Market Leader Across the Americas

• Local laboratory operations

• Sales teams throughout the Americas

• Comprehensive service offering

• Strong reputation among research institutions

• Scalable operating platform

3. Blue-Chip Customer Base

Trusted by leading universities, hospitals and global pharmaceutical companies, including:

• Stanford University
• University of California
• AbbVie
• Pfizer
• AstraZeneca
• Novo Nordisk
• Amgen
• Bristol Myers Squibb
• Gilead
• Sanofi

4. Proprietary Laboratory Automation

The Company has invested significantly in proprietary laboratory automation, delivering:

• 60% reduction in production cycle

• 400 samples/day per production line

• 25% higher production capacity
• 100% productivity improvement
• Industry-leading sequencing quality

These capabilities create meaningful barriers to entry while supporting strong operating leverage.

5. Highly Diversified Service Portfolio

The platform provides end-to-end solutions across:

• Next Generation Sequencing
• Single Cell Sequencing
• Epigenomics
• Metagenomics
• Proteomics
• Metabolomics
• Bioinformatics
• Custom Research Services

6. Experienced Scientific Management Team

The business is led by an experienced scientific leadership team with deep expertise in molecular biology, genomics, laboratory operations, and commercial development.

The existing management team is expected to provide operational continuity following the transaction.

7. Significant Value Creation Potential

Following separation from its listed parent company, investors will benefit from:

• Independent strategic direction
• Operational optimization
• Margin enhancement initiatives
• Geographic expansion
• New laboratory development
• Potential bolt-on acquisitions
• Long-term IPO or strategic exit opportunities

Transaction Overview

Opportunity

Acquisition of a controlling interest in a leading U.S.-based multi-omics platform.

Seller

Publicly listed multinational corporation.

Transaction Structure

Flexible transaction structure, including share acquisition and/or primary capital injection.

Expected Closing

Q4 2026.